PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

Getz Healthcare announced that it has partnered with Subtle Medical, a Menlo Park, CA-based healthcare technology company, to distribute the company's artificial intelligence (AI)-based software solutions for faster and safer medical imaging.
News | Artificial Intelligence
Subtle Medical Partners with Getz Healthcare to Improve Medical Imaging with AI-powered Technology

March 29, 2023 — In a partnership which aims to provide faster and safer medical imaging across Australia and New ...

Time March 29, 2023
arrow
News | PET Imaging
Nuclidium and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumors

March 23, 2023 — Nuclidium announced that the Neuroendocrine Tumors Research Foundation (NETRF) has selected the company ...

Time March 24, 2023
arrow
Positron Corporation, a molecular imaging device company that offers PET imaging systems and clinical services, is pleased to announce that it has executed a Clinical Study/Research Agreement with Ochsner Clinic Foundation
News | PET-CT
Positron Corporation Enters into Agreement with Ochsner Clinic Foundation for Clinical Study of its New “Affinity PET-CT 4D” Device

March 21, 2023 — Positron Corporation, a molecular imaging device company that offers PET imaging systems and clinical ...

Time March 21, 2023
arrow
Researchers found evidence of heart muscle inflammation in a small number of patients with acute myocarditis after COVID-19 vaccination, but not in patients without acute myocarditis
News | Coronavirus (COVID-19)
Study Examines Heart Inflammation after COVID Vaccine

March 10, 2023 — Researchers found evidence of heart muscle inflammation in a small number of patients with acute ...

Time March 10, 2023
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for somatostatin receptor (SSTR) PET imaging for patients with neuroendocrine tumors (NETs).
News | PET Imaging
Procedure Standard/practice Guideline Published for SSTR PET Imaging of Neuroendocrine Tumors

February 23, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of ...

Time February 23, 2023
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 09, 2023
arrow
Summary of the pilot study and preliminary PET imaging findings. Image created by R Wetherill, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
News | PET Imaging
PET Imaging Shows Greater Lung Inflammation in e-cigarette Users than Cigarette Smokers

January 31, 2023 — Electronic cigarette (e-cigarette) users have greater lung inflammation than cigarette smokers and ...

Time January 31, 2023
arrow
data showed that CytoSite’s Granzyme B (GzmB) PET imaging using [68Ga-NOTA]-hGZP (CSB-111) was feasible and safe in human subjects. These data come from a Phase I trial assessing the safety and feasibility of GzmB PET imaging in subjects with melanoma and non-small cell lung cancer (NSCLC) receiving KEYTRUDA (pembrolizumab).
News | Clinical Trials
CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting

December 14, 2022 — CytoSite Bio, a company developing precision imaging products that determine patient response to ...

Time December 14, 2022
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
arrow
A team led by UTHealth Houston's K. Lance Gould, MD, (center) used PET imaging technology (shown above) to map coronary blood flow and its outcomes among heart disease patients. (Photo by UTHealth Houston)
News | PET Imaging
PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Time December 01, 2022
arrow
18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)
News | PET Imaging
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time November 02, 2022
arrow
Top trends boosting the industry expansion through 2028
Feature | Contrast Media | By Shankar Khatkale
Imaging Contrast Agents Global Market Outlook

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

Time November 02, 2022
arrow
The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
News | PET Imaging
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
Company announces SCINTIX as new product name for its flagship biology-guided radiotherapy technology
News | PET-CT
RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022

October 24, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 24, 2022
arrow
18F-SMBT-1 PET studies showed that beta-amyloid+ Alzheimer’s disease (AD) patients, but most importantly, beta-amyloid+ controls (CN) have significantly higher regional 18F-SMBT-1 binding than beta-amyloid- CN, with 18F-SMBT-1 retention highly associated with beta-amyloid burden. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of beta-amyloid accumulation.
News | PET Imaging
Novel PET Imaging Agent Detects Earliest Signs of Alzheimer's Disease

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18F-rhPSMA-7.3 clinical data and images.
News | PET Imaging
Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3

October 19, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

September 28, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 28, 2022
arrow
Ground-breaking research funded by National Cancer Institute
News | PET-CT
Xoran Partners With WVU to Develop PET/CT Scanner for Head and Neck Cancers (HNCs)

September 28, 2022 — Xoran Technologies is engaged in a ground-breaking research project to develop a PET/CT scanner for ...

Time September 28, 2022
arrow
For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative imaging and service solutions to healthcare facilities regardless of their size, location or capital budget. That vision is as strong today as it was back in 1980.
News | PET-CT
SMS first to bring Mobile Digital PET/CT to North Dakota and Montana

September 13, 2022 — For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative ...

Time September 13, 2022
arrow
Patients with detectable PSA (0.2-2.0 ng/mL) post-prostatectomy considered for salvage radiotherapy undergoing 18F-DCFPyl PSMA PET/CT staging. Image created by M.Ng et al, GenesisCare, Melbourne, Australia.
News | Prostate Cancer
New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50% of Prostate Cancer Patients

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now